医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

European Patent Office Upholds Validity of Mitsubishi Chemical’s Patent on Biomass-based High-quality Polyester

2016年06月20日 PM08:31
このエントリーをはてなブックマークに追加


 

TOKYO

Mitsubishi Chemical Corporation (MCC; Head office: Chiyoda-ku, Tokyo; President: Hiroaki Ishizuka) today announced that the European Patent Office (EPO) on May 17 issued a notice maintaining the patent owned by MCC (EP1882712B; “the patent”), which is a basic patent for a biomass-based polyester. Several corporations and others had filed notices of opposition to the validity of the patent. However, the EPO largely sided with MCC’s position as to the patent’s validity following the oral proceedings on April 15 of this year.

It is a substance patent for a biomass-based high-quality polyester, and is vastly applicable for business activities such as manufacturing and sales. The corresponding patents have also been granted in Japan, the U.S., and China. The EPO’s decision supports the patent’s validity, and MCC will move proactively to defend the patent against future similar objections.

“MCC owns many other patents relating to biomass-based products. It continually expands its own businesses by utilizing those patents and provides licenses to other companies, in order to promote the spread of those products and contribute to global environmental sustainability,” stated Johei Takimoto, Chief Operation Officer, the Polymer Division.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160620005620/en/

CONTACT

For further information, please contact:
Mitsubishi Chemical
Holdings Corporation
Satoshi Kofukata, [+81] (0)3-6748-7140
Public
Relations and Investor Relations Office

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果